Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 193, Issue 3, Pages 1181-1186Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2005.06.036
Keywords
CRH levels; prediction; preterm delivery
Categories
Funding
- NICHD NIH HHS [HD27869, HD27861, HD27860, HD21414, HD36801, HD40500, HD21410, HD34116, HD27917, HD34122, HD34136, HD27915, HD40512, HD40544, HD34208, HD34210, HD27905, HD40560] Funding Source: Medline
Ask authors/readers for more resources
Objective: The purpose of this study was to examine the utility of a single second- trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery. Study design: This is an analysis of data from a multicenter placebo-con trolled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at < 37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to I ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at I I of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test. Results: The overall rates of preterm birth in this cohort of 170 patients were 35.9% at < 37 weeks (31.9% progesterone, 43.9% placebo), and 19.4% at < 35 weeks (18.6% vs 2 1. 1 %). The median levels of corticotropin-releasing hormone were similar between those delivering at < 37 weeks and those delivering >= 37 weeks (0.39 ng/mL vs 0.37 ng/mL, P = .08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at < 35 weeks or >= 35 weeks (0.36 vs 0.38, P =.90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at < 37 or >= 37 weeks (0.40 vs 0.41, P = .72) and at < 35 or >= 35 weeks (P = .64). Conclusion: A single measurement of corticotropin- releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication. (C) 2005 Mosby, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available